0001209191-20-013016.txt : 20200226
0001209191-20-013016.hdr.sgml : 20200226
20200226162910
ACCESSION NUMBER: 0001209191-20-013016
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200224
FILED AS OF DATE: 20200226
DATE AS OF CHANGE: 20200226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ALTSHULER DAVID
CENTRAL INDEX KEY: 0001550395
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 20656153
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-24
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001550395
ALTSHULER DAVID
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Global Research and CSO
Common Stock
2020-02-24
4
F
0
2416
239.23
D
31930
D
Common Stock
2020-02-25
4
S
0
734
229.72
D
31196
D
Common Stock
2020-02-25
4
S
0
400
230.77
D
30796
D
Common Stock
2020-02-25
4
S
0
400
232.51
D
30396
D
Common Stock
2020-02-25
4
S
0
574
234.52
D
29822
D
Common Stock
2020-02-25
4
S
0
280
235.53
D
29542
D
Common Stock
2020-02-25
4
S
0
160
236.80
D
29382
D
Common Stock
2020-02-25
4
S
0
480
238.33
D
28902
D
Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $229.72 (range $229.23 to $230.14).
Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $230.77 (range $230.29 to $231.27).
Open market sales reported on this line occurred at a weighted average price of $232.51 (range $232.33 to $233.04).
Open market sales reported on this line occurred at a weighted average price of $234.52 (range $234.22 to $234.82).
Open market sales reported on this line occurred at a weighted average price of $235.53 (range $235.43 to $235.72).
Open market sales reported on this line occurred at a weighted average price of $238.33 (range $238.16 to $238.54).
/s/ Omar White, Attorney-in-Fact
2020-02-26